Nifedipine for Hypertensive Emergencies

JAMA: The Journal of the American Medical Association

Volumn 277, Issue 10, 1997, Pages 787-788

  Semplicini, Andrea ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; NIFEDIPINE; NICARDIPINE;

CLINICAL PRACTICE; DRUG UTILIZATION; EMERGENCY; HUMAN; HYPERTENSION; NOTE; RISK; ABDOMINAL DISEASE; DRUG FATALITY; HEART ARRHYTHMIA; HEART INFARCTION; LETTER; PARALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUBLINGUAL DRUG ADMINISTRATION; SYNCOPE;

ANTIHYPERTENSIVE AGENTS; DRUG UTILIZATION; EMERGENCIES; HUMANS; HYPERTENSION; NIFEDIPINE; PHYSICIAN'S PRACTICE PATTERNS; RISK;

EID: 0031054170     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1997.03540340021015     Document Type: Letter

References (4)

1. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276:1328-1331.
2. Winker MA. The FDA's decision regarding new indications for approved drugs: where's the evidence? JAMA. 1996;276:1342-1343.
3. Ledingham JGG, Rajagopalan B. Cerebral complications in the treatment of accelerated hypertension. Q J Med. 1979;48:25-41.
4. Angeli P, Chiesa M, Caregaro L, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. Arch Intern Med. 1991;151:678-682.